The review's central contribution is unifying structural evidence that SUMO binds the E2 enzyme UBC9 on a distinct "backside" surface (~600 Γ Β² buried, low-Β΅M affinity) located opposite the SIM-binding groove, and that convergent hotspot residues β Tyr91 (Ο-Ο contacts) and Glu67 (salt bridges) β recur across E1 (SAE1/SAE2), E2 (UBC9), and proteases (SENP1, USPL1) . This mechanistic scaffold is anchored by the definitive quaternary crystal structure (PDB 1Z5S, 3.0 Γ , Rwork 0.247/Rfree 0.29), where Nup358/RanBP2 tethers SUMO and UBC9 to orient the thioester for conjugation :
The review's mechanistic claims are cross-validated by independent genetics: the fission-yeast sumo-D81R mutation β which disrupts the SUMOβUbc9 non-covalent contact β reduces Pli1-dependent SUMO chain formation and suppresses taz1Ξ telomere phenotypes, directly supporting backside binding as a chain-elongation determinant . Downstream regulatory layers reinforce the model: UBC9 SUMOylation at Lys-49 (adjacent to the backside) redirects it to PML nuclear bodies with anti-senescence effects independent of catalysis , while N-terminal residues R13/R17/H20 β not the backside K74/S89 surface β control nuclear retention via SUMO and Importin-13 . Phosphorylation adds another axis: CDK1-pS71 enables Pin1 isomerization of UBC9, selectively promoting SUMO1 thioester formation . Recent SIM-groove-mutant interactomics independently show much of the SUMO interactome β including UBC9 itself β depends on non-covalent SUMO surfaces .
Reported vs inferred: the ~600 Γ Β² and hotspot-residue assignments are reported from PDB-derived structural analyses; their cellular importance is largely inferred from yeast genetics and truncated-complex crystallography. Blind spots the review itself acknowledges: quantitative affinity data are sparse for SUMO4/5 and paralogue-specific contacts; structural data skew toward crystallizable human/yeast fragments, so full-length Nup358 or chromatin-bound UBC9 dynamics are untested; narrative-review format risks publication bias toward well-characterized interfaces . What would change this conclusion: demonstrating that backside-interface mutants (e.g., D81R-equivalents in human SUMO2) leave cellular SUMO chain formation intact despite the in vitro defects, or single-molecule kinetics showing backside binding is dispensable in vivo.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.